Please use this identifier to cite or link to this item:
|Title:||Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer||Authors:||Chin, L.P.
|Keywords:||Anaplastic lymphoma kinase inhibitors
Non-small-cell lung cancer
|Issue Date:||Nov-2012||Citation:||Chin, L.P., Soo, R.A., Soong, R., Ou, S.-H.I. (2012-11). Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. Journal of Thoracic Oncology 7 (11) : 1625-1630. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e31826baf83||Abstract:||Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme. Recently, clinicopathologic characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described. Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clinical trial in this molecular subset of NSCLC patients. This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors. Copyright © 2012 by the International Association for the Study of Lung Cancer.||Source Title:||Journal of Thoracic Oncology||URI:||http://scholarbank.nus.edu.sg/handle/10635/115550||ISSN:||15560864||DOI:||10.1097/JTO.0b013e31826baf83|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 12, 2019
WEB OF SCIENCETM
checked on Jul 10, 2019
checked on Nov 8, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.